Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

详细信息    查看全文

• 作者：A. Murray Brunt^a ; ^{Murray.Brunt@uhns.nhs.uk" class="auth_mail" title="E-mail the corresponding author} ; Duncan Wheatley^b ; John Yarnold^c ; Navita Somaiah^d ; Stephen Kelly^e ; Adrian Harnett^f ; Charlotte Coles^g ; Andrew Goodman^h ; Amit Bahlⁱ ; Mark Churn^j ; Rada Zotova^k ; Mark Sydenham^l ; Clare L Griffin^l ; James P Morden^l ; Judith M Bliss^l ; on behalf of the FAST-Forward Trial Management Group
• 关键词：Breast cancer ; Radiotherapy ; Hypofractionation
• 刊名：Radiotherapy and Oncology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：120
• 期：1
• 页码：114-118
• 全文大小：444 K

文摘

FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions.

Material and methods

Patients were randomly allocated to 40 Gy/15 fractions (F)/3-weeks, 27 Gy/5F/1-week or 26 Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 weeks after completion.

Results

190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%); 26 Gy/5F 0/53.

Conclusions

Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.